Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 February 2006, Vol. 107, No. 3, pp. 847-848.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Durbin, J. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Durbin, J. E.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Next Article next article arrow


InsideBlood

IMMUNOBIOLOGY

Comment on Gil et al, page 987

Ignoring type 1 interferons

Joan E. Durbin

OHIO STATE UNIVERSITY

Modulation of STAT1 levels in virus-specific CD8 T cells allows rapid clonal expansion in the presence of type I interferons.

In response to an acute viral infection, naive CD8 T cells triggered by antigen undergo a massive expansion that peaks approximately one week later in most infection models. This antigen-specific CD8 T-cell population is essential for clearance of many viral pathogens; prior to their appearance virus spread is held in check, but not contained, by innate immune defenses. Type 1 ({alpha} and beta) interferons (IFNs), produced within hours of infection, play a major role in the earliest host response by inducing a large number of genes that can inhibit virus replication in susceptible cell types. Beyond these direct antiviral effects, IFN-{alpha}/beta serve many additional functions, such as stimulating maturation of antigen-presenting dendritic cells and limiting nonspecific immune-cell proliferation.

The signaling pathway used by type 1 IFNs has been very well characterized. When activated by ligand binding, the receptor-associated tyrosine kinases, TYK2 and JAK1, phosphorylate the IFN-{alpha}/beta receptor subunit 1, which then serves as a binding site for STAT2. Tyrosine phosphorylation of bound STAT2 allows STAT1 binding and its activation by phosphorylation on Y701. The activated STAT proteins are then able to form the heterotrimeric ISGF3 (interferon-stimulated gene factor 3) complex, composed of STAT1, STAT2, and IRF9, which moves into the nucleus and mediates transcriptional up-regulation of IFN-responsive genes. But while the details of IFN-{alpha}/beta signaling are well understood at the level of the single cell, the larger problem of explaining how the various in vivo effects of IFN-{alpha}/beta are simultaneously regulated remains. In this issue, a paper by Gil and colleagues shines new light onto this larger question by asking how antigen-specific T cells can proliferate rapidly in the presence of type 1 IFN concentrations sufficient to inhibit T-cell growth. The authors address this paradox by demonstrating first that the antiproliferative effects of IFN-{alpha}/beta are STAT1 dependent and secondly, that as infection progresses, STAT1 levels decline in the antigen-specific CD8 T-cell subset. This is in contrast to other splenic leukocytes, including nonproliferating CD8 T cells, in which STAT1 levels are enhanced (see figure). Although this group has previously shown that type 1 IFN effects will vary depending on the ratio of STAT1 and STAT4 expression,1 this is the first demonstration of STAT1 modulation within a particular cell type in the course of a virus infection. Down-regulation of STAT1 protein levels following activation of CD8 lymphocytes through the T-cell receptor allows these cells to ignore type 1 IFNs and continue to expand even in their presence. This is consistent with a recent report that type 1 IFNs promote rather than inhibit the proliferative response to mitogenic stimuli by T cells lacking either Stat1 or Stat2.2 Thus, the nuanced regulation of JAK/STAT signaling in vivo that is revealed by Gil et al resolves a number of apparent contradictions by uncovering yet another layer of complexity in the host IFN response to viral pathogens. {blacksquare}


Figure 1
View larger version (54K):
[in this window]
[in a new window]
 
Virus infection is quickly followed by production of type I IFNs. These cytokines will antagonize viral replication but also act to inhibit T-cell expansion in a STAT1 dependent manner (top). Gil et al now show that rapidly dividing (CSFE10), virus-specific T cells overcome this block to proliferation by down-modulating the level of STAT1 protein available for transducing signals from the IFN-{alpha}beta receptor (bottom). Illustration by Kenneth Probst.

 
References

  1. Nguyen KB, Watford W, Salomon R, et al. Critical role for STAT4 activation by Type I IFNs in the IFN-{gamma} response to viral infection. Science. 2002;297: 2063-2066.[Abstract/Free Full Text]

  2. Gimeno R, Lee CK, Schindler C, Levy DE. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. J Immunol. 2005;25: 5456-5465.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo
M. Pilar Gil, Rachelle Salomon, Jennifer Louten, and Christine A. Biron
Blood 2006 107: 987-993. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Durbin, J. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Durbin, J. E.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020